Quantcast

Latest Alexza Pharmaceuticals Inc. Stories

2014-08-14 08:30:05

First Patient Dosed in the EU Post-Authorization Safety Study MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE(®) inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies: -- a benzodiazepine interaction study - study completed and data...

2014-08-08 08:26:35

First ADASUVE Launch in Latin America MOUNTAIN VIEW, Calif., Aug. 8, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries. Ferrer introduced ADASUVE during a...

2014-07-31 16:29:24

AZ-002 Phase 2a Study in Patients with Epilepsy Planned for Second Half of 2014 MOUNTAIN VIEW, Calif., July 31, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato(®) alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has...

2014-07-29 16:27:57

MOUNTAIN VIEW, Calif., July 29, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below: -- 2014 Avondale Partners Healthcare 1-1 Conference,...

2014-07-17 16:26:43

MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results....

2014-06-30 16:26:55

MOUNTAIN VIEW, Calif., June 30, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities. Dr. Kamemoto has been Alexza's Vice President, Regulatory Affairs since July 2012. He joined Alexza in 2006 as...

2014-05-05 16:27:31

Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter was $10.7 million compared to $20.7 million during the same quarter in 2013. At March 31, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and...

2014-04-30 16:30:47

MOUNTAIN VIEW, Calif., April 30, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in the Nordic countries (Sweden, Norway, Denmark and Finland). Grupo Ferrer Internacional, S.A. ("Ferrer") is commercializing ADASUVE in the Nordic countries through a distribution agreement with Medivir AB. Ferrer is Alexza's commercial partner for ADASUVE in the Europe, Latin America and the...

2014-04-17 08:28:57

MOUNTAIN VIEW, Calif., April 17, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Winston R. Brown, Jr. has joined the Company as Vice President, Quality. Mr. Brown brings more than two decades of experience in global quality, regulatory compliance and development operations working with diverse biopharmaceuticals, medical devices and nutritionals in globally integrated companies. In this position, Mr. Brown has primary responsibility for Quality...

2014-04-16 16:30:48

MOUNTAIN VIEW, Calif., April 16, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended March 31, 2014 on Monday, May 5, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results....


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related